Stock comparison
AxoGen
Haemonetics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
AXGN
AxoGen
Market cap
$2.17B
Sector
Healthcare
HAE
Haemonetics
Market cap
$2.98B
Sector
Healthcare
Overall winner
Haemonetics HAE
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | AXGN | HAE | Winner |
|---|---|---|---|
| Warren Buffett | 19F | 70B | HAE |
| Benjamin Graham | 54D | 85A | HAE |
| Philip Fisher | 40D | 60C | HAE |
| Peter Lynch | 27F | 54C | HAE |
| Joel Greenblatt | 0F | 31F | HAE |
| Charlie Munger | 26F | 54D | HAE |
| Terry Smith | 27F | 55D | HAE |
Side-by-side metrics
| Metric | AXGN | HAE |
|---|---|---|
| Market cap | $2.17B | $2.98B |
| P/E (TTM) | - | 24.8x |
| EV/EBIT | - | 14.1x |
| ROIC (TTM) | -3.4% | 8.37% |
| Gross margin | 75.01% | 55.74% |
| Net margin | -13.21% | 7.29% |
| Revenue CAGR 5y | 15.32% | 7.65% |
| EPS CAGR 5y | - | 24.62% |
| Debt / Equity | 0.1x | 1.5x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
AXGN leads on
- P/E (TTM)-vs 24.8x+136%
- EV/EBIT-vs 14.1x+105%
- Debt / Equity0.1xvs 1.5x+95%
- Revenue CAGR 5y15.32%vs 7.65%+50%
HAE leads on
- Net margin7.29%vs -13.21%+155%
- ROIC (TTM)8.37%vs -3.4%+141%
- Market cap$2.98Bvs $2.17B+27%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.